Change in expression of ER, bcl-2 and MIB1 on primary tamoxifen and relation to response in ER positive breast cancer (Q43549612)

24 November 2017

title

Change in expression of ER, bcl-2 and MIB1 on primary tamoxifen and relation to response in ER positive breast cancer (English)

1 reference

24 November 2017

1 reference

3

1 reference

24 November 2017

5

Pinder SE

1 reference

24 November 2017

6

Ellis IO

1 reference

24 November 2017

Kenny FS

1

1 reference

24 November 2017

Willsher PC

series ordinal

2

1 reference

24 November 2017

Nicholson R

series ordinal

4

1 reference

24 November 2017

Robertson JF

series ordinal

7

1 reference

24 November 2017

language of work or name

English

0 references

publication date

1 January 2001

1 reference

Breast Cancer Research and Treatment

24 November 2017

published in

1 reference

24 November 2017

volume

65

1 reference

24 November 2017

issue

2

1 reference

24 November 2017

page(s)

135-144

1 reference

https://scigraph.springernature.com/pub.10.1023/a:1006469627067

24 November 2017

exact match

0 references

cites work

Cellular effects of tamoxifen in primary breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006469627067

Oestrogen receptor: a stable phenotype in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006469627067

Pharmacokinetics, pharmacological and anti-tumour effects of the specific anti-oestrogen ICI 182780 in women with advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006469627067

pS2 protein: a marker improving prediction of response to neoadjuvant tamoxifen in post-menopausal breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006469627067

Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006469627067

Use of tamoxifen for breast cancer: twenty-eight years later

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006469627067

Effect of tamoxifen on Ki67 labelling index in human breast tumours and its relationship to oestrogen and progesterone receptor status.

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006469627067

Antiestrogen regulation of cell cycle progression and cyclin D1 gene expression in MCF-7 human breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006469627067

Hormone sensitivity in breast cancer: influence of heterogeneity of oestrogen receptor expression and cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006469627067

Bcl-2 and the regulation of programmed cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006469627067

Prognostic value of bcl-2 expression in invasive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006469627067

Effects of tamoxifen on growth and apoptosis of estrogen-dependent and -independent human breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006469627067

Relationship of PS2 with response to tamoxifen therapy in patients with recurrent breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006469627067

Duration of remission to ICI 182,780 compared to megestrol acetate in tamoxifen resistant breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006469627067

Effects of short-term antiestrogen treatment of primary breast cancer on estrogen receptor mRNA and protein expression and on estrogen-regulated genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006469627067

Oestrogen and progesterone receptors as prognostic variables in hormonally treated breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006469627067

7 January 2021

Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006469627067

7 January 2021

Assessment of response to therapy in advanced breast cancer: a project of the Programme on Clinical Oncology of the International Union Against Cancer, Geneva, Switzerland

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006469627067

7 January 2021

Prediction of endocrine response in breast cancer by immunocytochemical detection of oestrogen receptor in fine-needle aspirates

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006469627067

7 January 2021

Short-term effects of pure anti-oestrogen ICI 182780 treatment on oestrogen receptor, epidermal growth factor receptor and transforming growth factor-alpha protein expression in human breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006469627067

7 January 2021

Immunocytochemical localization of BCL-2 protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006469627067

7 January 2021

Gamma linolenic acid with tamoxifen as primary therapy in breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006469627067

7 January 2021

A new immunohistochemical antibody for the assessment of estrogen receptor status on routine formalin-fixed tissue samples

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006469627067

7 January 2021

Methodology of immunohistological detection of oestrogen receptor in human breast carcinoma in formalin-fixed, paraffin-embedded tissue: a comparison with frozen section methodology

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006469627067

7 January 2021

bcl-2, p53, and response to tamoxifen in estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group study

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006469627067

7 January 2021

Modulation of Bcl-2 and Ki-67 expression in oestrogen receptor-positive human breast cancer by tamoxifen

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006469627067

7 January 2021

Changes in hormone receptors and proliferation markers in tamoxifen treated breast cancer patients and the relationship with response

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006469627067

7 January 2021

The expression of Ki-S1 and BCL-2 and the response to primary tamoxifen therapy in elderly patients with breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006469627067

7 January 2021

Apoptosis suppressing protein bcl-2 is expressed in well-differentiated breast carcinomas with favourable prognosis

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006469627067

7 January 2021

Bcl-2 protein expression in breast cancer in relation to established prognostic factors and other clinicopathological variables

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006469627067

7 January 2021

Clinical significance of bcl-2 gene expression in human breast cancer tissues

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006469627067

7 January 2021

Induction of progesterone receptor with tamoxifen in human breast cancer with special reference to its behavior over time

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006469627067

7 January 2021

Identifiers

DOI

10.1023/A:1006469627067

1 reference

Dimensions Publication ID

24 November 2017

1016547350

0 references

1 reference